Johnson & Johnson (JNJ) halted a clinical trial of its antibiotic Doribax after more pneumonia patients who took the product died and fewer were cured, regulators said.
Doribax, already approved for urinary and abdominal infections in the U.S., is still considered safe and effective for those uses, the Food and Drug Administration said today in a statement on its website. The trial tested the drug in pneumonia patients who were on ventilators, an indication for which it’s approved in Europe.
Doribax, already approved for urinary and abdominal infections in the U.S., is still considered safe and effective for those uses, the Food and Drug Administration said today in a statement on its website. The trial tested the drug in pneumonia patients who were on ventilators, an indication for which it’s approved in Europe.
